Genetic characteristics and prognosis of m6A RNAmethylation regulator in acute myeloid leukemia

Background: To identify the genetic characteristics of m6A RNA methylation regulators in AML and explore their potential value as prognostic markers.Methods: RNA-seq transcriptome data and clinical survival data of acute myeloid leukemia (AML) were downloaded from ICGC and TCGA, gene annotation files were downloaded from GENECODE (1). 13 widely reported m6A RNA alphas were obtained from the literature. The expression of m6A RNA methylation regulators were collected and analized using gene annotation files. The samples were subjected to consistent clustering to obtain two subgroups RM1 and RM2, and the pathological characteristics and survival between the two subgroups were analyzed. Comparative analysis and functional analysis of m6A RNA methylation regulators between subgroups were completed. The STRING database analyzed the interactions between m6A RNA methylation regulators, and Spearman analyzed the correlation of expression of m6A RNA methylation regulators. COX regression analysis and risk scores were used to predict prognosis and pathological characteristics, and risk scores calculated using features were used to predict the prognosis and clinicopathological characteristics of tumor patients.Results: According to the morphological characteristics of AML, the samples were divided into 8 categories (M0 Undifferentiated, M1, M2, M3, M4, M5, M6, M7), and among them, the expression profile and expression heat map of 13 m6A RNA methylation regulators were constructed. Using m6A RNA methylation regulator as a feature vector, consistent clustering of 151 samples yielded two subgroups RM1 and RM2. Among them, the expression of the regulator in RM1 was higher than RM2,and RM2 patients had a longer survival time than RM1. Gene set enrichment analysis found that functional processes such as endothelial-hematopoietic transformation through the Notch pathway were significantly enriched in RM1. The analysis of the KM curve indicates that when the expression of FTO or ALKBH5 or of ZC3H13 was low, the survival time of patients was significantly higher than that with high expression.Conclusion: m6A RNA methylase regulator is not only an independent prognostic marker of AML, but also can predict its clinicopathological characteristics, which has potential value for stratifying prognosis and improving treatment strategies.